WO2019072130A1 - Composé de 1,2,4-triazole - Google Patents
Composé de 1,2,4-triazole Download PDFInfo
- Publication number
- WO2019072130A1 WO2019072130A1 PCT/CN2018/109045 CN2018109045W WO2019072130A1 WO 2019072130 A1 WO2019072130 A1 WO 2019072130A1 CN 2018109045 W CN2018109045 W CN 2018109045W WO 2019072130 A1 WO2019072130 A1 WO 2019072130A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- disease
- pharmaceutically acceptable
- acceptable salt
- triazole compound
- Prior art date
Links
- 0 *C(*)(*)[n]1c(-c2nc(NC(c3c(*)c(-[n]4c(*)nc(C(*)(C5(*)*)C5(*)N)c4*)c(*)c(*)c3F)=O)c(*)c(*)c2*)nnc1* Chemical compound *C(*)(*)[n]1c(-c2nc(NC(c3c(*)c(-[n]4c(*)nc(C(*)(C5(*)*)C5(*)N)c4*)c(*)c(*)c3F)=O)c(*)c(*)c2*)nnc1* 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne un composé de 1,2,4-triazole représenté par la formule (I) et des sels pharmaceutiquement acceptables de celui-ci. Le composé selon l'invention possède une activité d'un inhibiteur de kinase 1 régulatrice de signal d'apoptose (" ASK1 ") ; ainsi, le composé peut être utilisé pour traiter des maladies induites par ASK1 notamment une maladie hépatique chronique, une maladie cardiovasculaire, une perturbation métabolique, un trouble du système respiratoire, un trouble gastro-intestinal et des maladies neurodégénératives. L'invention concerne également une composition pharmaceutique comprenant le composé de formule (I) et ses utilisations.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710945318 | 2017-10-12 | ||
CN201710945318.0 | 2017-10-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019072130A1 true WO2019072130A1 (fr) | 2019-04-18 |
Family
ID=65054891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2018/109045 WO2019072130A1 (fr) | 2017-10-12 | 2018-09-30 | Composé de 1,2,4-triazole |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN109232538B (fr) |
WO (1) | WO2019072130A1 (fr) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104080771A (zh) * | 2012-01-27 | 2014-10-01 | 吉利德科学公司 | 细胞凋亡信号调节激酶抑制剂 |
CN107108519A (zh) * | 2014-12-23 | 2017-08-29 | 吉利德科学公司 | 制备ask1抑制剂的方法 |
WO2018157857A1 (fr) * | 2017-03-03 | 2018-09-07 | 江苏豪森药业集团有限公司 | Inhibiteur de kinase de régulation du signal apoptotique, son procédé de préparation et son application |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI598347B (zh) * | 2009-07-13 | 2017-09-11 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
EP2588475B1 (fr) * | 2010-07-02 | 2015-05-20 | Gilead Sciences, Inc. | Inhibiteurs des kinases régulant les signaux de l'apoptose |
AP2016009248A0 (en) * | 2013-12-20 | 2016-05-31 | Gilead Sciences Inc | Apoptosis signal-regulating kinase inhibitors |
MA41252A (fr) * | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
-
2018
- 2018-09-30 CN CN201811159093.7A patent/CN109232538B/zh active Active
- 2018-09-30 CN CN202010554939.8A patent/CN111518080A/zh active Pending
- 2018-09-30 WO PCT/CN2018/109045 patent/WO2019072130A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104080771A (zh) * | 2012-01-27 | 2014-10-01 | 吉利德科学公司 | 细胞凋亡信号调节激酶抑制剂 |
CN107108519A (zh) * | 2014-12-23 | 2017-08-29 | 吉利德科学公司 | 制备ask1抑制剂的方法 |
WO2018157857A1 (fr) * | 2017-03-03 | 2018-09-07 | 江苏豪森药业集团有限公司 | Inhibiteur de kinase de régulation du signal apoptotique, son procédé de préparation et son application |
Also Published As
Publication number | Publication date |
---|---|
CN111518080A (zh) | 2020-08-11 |
CN109232538B (zh) | 2020-07-24 |
CN109232538A (zh) | 2019-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2017128605A (ja) | 抗ウイルス化合物の固体形態 | |
JP6317320B2 (ja) | 上皮成長因子受容体キナーゼ阻害剤の塩 | |
CN113784963B (zh) | 用作ret激酶抑制剂的化合物及其应用 | |
CN109311832B (zh) | 沃替西汀的帕莫酸盐及其晶型 | |
KR101424013B1 (ko) | 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산의 결정형과 그의 제조방법 | |
US20160214939A1 (en) | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof | |
JP2021523918A (ja) | Tlr7/tlr8阻害剤の結晶形態 | |
UA125516C2 (uk) | Заміщені діазагетеробіциклічні сполуки та їх застосування | |
JP5575979B2 (ja) | シアノ基を含有するチエノピリジンエステル誘導体、その調製方法、使用および組成物 | |
WO2021213317A1 (fr) | Inhibiteur de hpk1, son procédé de préparation et son utilisation | |
MX2012009964A (es) | Sales cristalinas de un potente inhibidor del hcv. | |
CN105026362B (zh) | 双环化合物 | |
TW201643143A (zh) | 抑制氧化壓迫引發的神經細胞死亡之化合物 | |
JP2021523120A (ja) | セルデュラチニブ(cerdulatinib)の固体形態 | |
JP6178799B2 (ja) | アプレピタントl−プロリン溶媒和化合物−組成物及び共結晶 | |
WO2021129841A1 (fr) | Composé utilisé comme inhibiteur de kinase ret et son application | |
JP2023502675A (ja) | 核タンパク質阻害剤の結晶形及びその使用 | |
WO2023193563A1 (fr) | Forme cristalline d'un composé thiénopyridine, son procédé de préparation et composition pharmaceutique associée | |
WO2022194252A1 (fr) | Formes polymorphes de composé, leur procédé de préparation et leur utilisation | |
TWI782523B (zh) | 用作ret激酶抑制劑的化合物及其應用 | |
WO2019072130A1 (fr) | Composé de 1,2,4-triazole | |
EP4273139A1 (fr) | Dérivé de 2-pyridone, son procédé de préparation et son application pharmaceutique | |
JP5042861B2 (ja) | 結晶性1H−イミダゾ[4,5−b]ピリジン−5−アミン,7−[5−[(シクロヘキシルメチルアミノ)−メチル]−1H−インドール−2−イル]−2−メチル,硫酸塩(1:1),三水和物およびその医薬的使用 | |
JP2023539639A (ja) | Ssao阻害剤の多形 | |
JP7357634B2 (ja) | Urat-1阻害剤の新規塩型 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18866718 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18866718 Country of ref document: EP Kind code of ref document: A1 |